Merck, Inc.
Safety of a Three-Day Fosaprepitant Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-045)
- Conditions
- Chemotherapy-induced Nausea and Vomiting
- Interventions
- First Posted Date
- 2019-08-13
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 103
- Registration Number
- NCT04054193
- Locations
- 🇺🇸
Children's Hospitals and Clinics of Minnesota ( Site 1109), Minneapolis, Minnesota, United States
🇵🇪Instituto Nacional de Enfermedades Neoplasicas ( Site 1502), Lima, Peru
🇺🇸Phoenix Childrens Hospital ( Site 1101), Phoenix, Arizona, United States
Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025)
- Conditions
- Pneumococcal Infections
- Interventions
- First Posted Date
- 2019-07-24
- Last Posted Date
- 2023-07-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1184
- Registration Number
- NCT04031846
- Locations
- 🇧🇪
O.L.V. Ziekenhuis Aalst ( Site 0144), Aalst, Belgium
🇧🇪AZ Sint Jan Brugge-Oostende ( Site 0147), Brugge, Belgium
🇪🇸Centro de Salud Paiporta ( Site 0117), Paiporta, Valencia, Spain
Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2019-07-23
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 165
- Registration Number
- NCT04029480
- Locations
- 🇺🇸
Memorial Regional Hospital-Joe DiMaggio Children's Hospital Division of Pediatric Endocrinology ( Si, Hollywood, Florida, United States
🇺🇸William Beaumont Hospital ( Site 2219), Royal Oak, Michigan, United States
🇺🇸ICCT Research International, Inc. ( Site 2211), Chicago, Illinois, United States
Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026)
- Conditions
- Pneumococcal Infections
- Interventions
- First Posted Date
- 2019-07-11
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1191
- Registration Number
- NCT04016714
- Locations
- 🇫🇮
Kokkolan rokotetutkimusklinikka ( Site 0029), Kokkola, Mellersta Osterbotten, Finland
🇮🇹IRCCS Ospedale Policlinico San Martino ( Site 0042), Genova, Italy
🇩🇰Odense Universitetshospital ( Site 0001), Odense C, Syddanmark, Denmark
Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016)
- First Posted Date
- 2019-07-01
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 242
- Registration Number
- NCT04003103
- Locations
- 🇺🇸
Research Centers of America, LLC ( Site 0007), Hollywood, Florida, United States
🇺🇸Magee Womens Research Institute ( Site 0001), Pittsburgh, Pennsylvania, United States
🇺🇸Celerion, Inc. ( Site 0006), Lincoln, Nebraska, United States
Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)
- Conditions
- Biliary Tract Carcinoma
- Interventions
- First Posted Date
- 2019-07-01
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1069
- Registration Number
- NCT04003636
- Locations
- 🇺🇸
UCLA Hematology/Oncology - Santa Monica ( Site 0014), Los Angeles, California, United States
🇺🇸Hartford Hospital ( Site 0057), Hartford, Connecticut, United States
🇺🇸Winship Cancer Institute of Emory University ( Site 0013), Atlanta, Georgia, United States
Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023)
- Conditions
- Papillomavirus Infections
- Interventions
- First Posted Date
- 2019-06-26
- Last Posted Date
- 2022-11-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 6000
- Registration Number
- NCT03998254
- Locations
- 🇨🇳
Lingchuan Center for Disease Control and Prevention ( Site 0002), Guilin, Guangxi, China
🇨🇳Quanzhou Center for Disease Control and Prevention ( Site 0001), Guilin, Guangxi, China
🇨🇳Xiangyuan Center for Disease Control and Prevention ( Site 0003), Changzhi, Shanxi, China
Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)
- Conditions
- Carcinoma, Nonsquamous Non-small-cell Lung
- Interventions
- First Posted Date
- 2019-06-06
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1003
- Registration Number
- NCT03976323
- Locations
- 🇺🇸
Renovatio Clinical ( Site 0062), The Woodlands, Texas, United States
🇦🇺Liverpool Hospital ( Site 1201), Liverpool, New South Wales, Australia
🇨🇦Stronach Regional Cancer Centre ( Site 0101), Newmarket, Ontario, Canada
Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)
- Conditions
- Metastatic Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2019-06-06
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 422
- Registration Number
- NCT03976375
- Locations
- 🇺🇸
Harry & Jeanette Weinberg Cancer Institute ( Site 1626), Baltimore, Maryland, United States
🇺🇸Massachusetts General Hospital ( Site 1622), Boston, Massachusetts, United States
🇫🇷ICO Centre Paul Papin ( Site 0412), Angers, Maine-et-Loire, France
A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)
- Conditions
- Carcinoma, Squamous Cell, Non-small-cell Lung
- Interventions
- First Posted Date
- 2019-06-06
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 851
- Registration Number
- NCT03976362
- Locations
- 🇦🇷
Sanatorio Privado San Geronimo S.R.L ( Site 0510), Santa Fe, Argentina
🇺🇸Thompson Cancer Survival Center ( Site 2812), Knoxville, Tennessee, United States
🇦🇹Social Medical Center - Otto Wagner Hospital ( Site 1301), Vienna, Wien, Austria